PI3K at the crossroads of tumor angiogenesis signaling pathways
Open Access
- 26 February 2015
- journal article
- review article
- Published by Taylor & Francis in Molecular & Cellular Oncology
- Vol. 2 (2) , e975624
Abstract
Tumors need blood vessels for their growth, thus providing the rationale for antiangiogenic therapy in cancer treatment. However, intrinsic and acquired resistance and low response rates have turned out to be major limitations of antiangiogenic therapy. This emphasizes the need to further understand how the vasculature in cancer can be targeted. Although endothelial cells (ECs) rely on multiple growth factors and cytokines to grow, antiangiogenic therapies have mainly centered on targeting vascular endothelial growth factor (VEGF). Phosphoinositide 3-kinases (PI3Ks) form a family of 8 isoenzymes with non-redundant functions in normal biology and cancer. The subgroup of class I PI3Ks are situated at the crossroad of a plethora of proangiogenic signals and control cell growth, survival, motility, and metabolism. These isoenzymes have pleiotropic roles in the tumor microenvironment, including cell-autonomous functions in ECs, underscoring the complexity of targeting this pathway in cancer. Here, we describe ...Keywords
This publication has 83 references indexed in Scilit:
- miR-221 Is Required for Endothelial Tip Cell Behaviors during Vascular DevelopmentDevelopmental Cell, 2012
- Basic and Therapeutic Aspects of AngiogenesisCell, 2011
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and ProgressionCancer Cell, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Should individual PI3 kinase isoforms be targeted in cancer?Current Opinion in Cell Biology, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- miR-126 Regulates Angiogenic Signaling and Vascular IntegrityDevelopmental Cell, 2008
- PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesisCellular Signalling, 2007
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971